In immunotherapy‐favored cancers, using ROI‐ST, a study involving 152 non‐small cell lung cancer (NSCLC) patients revealed that the spatially enriched 163+ tumor‐associated macrophages (TAM) in the TME are associated with immunotherapy resistance, driven by the upregulation of CD27, ITGAM, and CCL5 expression within the tumor cavity.190. The gene discussed is CCL5; the disease is neoplasm.